| Application no. and date | 17781429.0 (espacenet) (Federated) (European Patent Register), 20170928 | | Patent/reg. no. and date | DK/EP 3518930, 20230308 | | Publication date | 20190807 | | Priority no. and date | EP 16191456, 20160929 | | EP pub. no. and date |
EP 3518930 20190807 | | Effective date | | | Applicant/owner | Ascendis Pharma Growth Disorders A/S, Tuborg Boulevard 12, 2900 Hellerup, DK | | Applicant ref. no. | V455412DK00 | | Inventor | SPROGØE, Kennett, c/o Ascendis Pharma A/S
Tuborg Boulevard 12, 2900 Hellerup, DK,
HOLTEN-ANDERSEN, Lars, c/o Ascendis Pharma A/S Tuborg Boulevard 12, 2900 Hellerup, DK,
MILLER BREINHOLT, Vibeke, c/o Ascendis Pharma A/S
Tuborg Boulevard 12, 2900 Hellerup, DK | | Representative | Zacco Denmark A/S, Arne Jacobsens Allé 15, 2300 København S | | Opponent | | | IPC Class | A61K 31/505 (2006.01) , A61K 38/22 (2006.01) , A61K 38/27 (2006.01) , A61K 47/60 (2017.01) , A61P 19/08 (2006.01) | | Title | Kombinationsbehandling af en CNP-agonist med kontrolleret frigivelse | | Int. application no. | EP2017074596 | | Int. publication no. | WO2018060314 | | Related patent (certificate) | | | Status | Rettet DK/EP patent | | Pædiatrisk forlængelse | - | | Udløbsdato for pædiatrisk forlængelse | - |
|
